Augmenting Language Therapy for Aphasia: Levodopa

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Nonfluent AphasiaStroke
Interventions
DRUG

levodopa/carbidopa

The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.

DRUG

Placebo comparator

The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.

Trial Locations (1)

60611

Center for Aphasia Research & Treatment, Chicago

All Listed Sponsors
collaborator

U.S. Department of Education

FED

lead

Shirley Ryan AbilityLab

OTHER

NCT01429077 - Augmenting Language Therapy for Aphasia: Levodopa | Biotech Hunter | Biotech Hunter